Durvalumab + Tremelimumab for Rare Cancers
Trial Summary
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications, but you must not have had chemotherapy or certain steroids within 28 days before starting the trial.
What data supports the effectiveness of the drug combination Durvalumab and Tremelimumab for rare cancers?
Is the combination of Durvalumab and Tremelimumab safe for humans?
How is the drug combination of Durvalumab and Tremelimumab unique for treating rare cancers?
The combination of Durvalumab and Tremelimumab is unique because it uses two immune checkpoint inhibitors that work together to enhance the body's immune response against cancer cells, which may offer benefits over using either drug alone. This approach is being explored for its potential to improve outcomes in rare cancers, where standard treatments may not exist.12569
What is the purpose of this trial?
This is an investigator initiated single institution, open-label study to evaluate the antitumor activity, safety, and tolerability of durvalumab in combination with tremelimumab in subjects with select advanced rare solid tumors.
Research Team
William J Edenfield, MD
Principal Investigator
Prisma Health-Upstate
Eligibility Criteria
This trial is for adults with rare advanced solid tumors who've had no luck with standard treatments or can't receive them. They should be relatively active (ECOG 0-2), able to undergo a tumor biopsy, and have their major organs functioning well. People who've previously used durvalumab, tremelimumab, or similar drugs; those with untreated brain metastases; recent steroid users; and patients with certain autoimmune diseases or other specific cancers under study elsewhere are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose-Exploration
Completed phase to explore dosing across a range of tumor types
Dose-Expansion
Ongoing phase including certain soft tissue sarcomas, neuroendocrine tumors, and thymic carcinoma
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Durvalumab and Tremelimumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Prisma Health-Upstate
Lead Sponsor
AstraZeneca
Industry Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
MedImmune LLC
Industry Sponsor
Dr. Reginald Seeto
MedImmune LLC
Chief Medical Officer since 2008
MD from University of Sydney, B.Sc. from University of Sydney
Peter Greenleaf
MedImmune LLC
Chief Executive Officer since 2006
MBA from St. Joseph’s University, B.S. from Western Connecticut State University